Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
In a study of 37,887 men 50 to 60 years old, those with PSA of >= 3 ng/ml underwent MRI imaging of the prostate and were randomized to systematic biopsy plus targeted biopsy or MRI-targeted biopsy only. MRI-directed targeted biopsy reduced the risk of overdiagnosis by half but did delay detection of intermediate-risk tumors in a small proportion of patients.
Internal Medicine December 21st 2022
JAMA Network
In this cohort analysis, which included male patients examined at 128 US Veterans Health Administration facilities between 2005 (n = 4,678,412) and 2019 (n = 5,371,701), facilities with greater rates of prostate-specific antigen screening showed lower rates of eventual metastatic prostate cancer incidence.
Oncology, Medical October 31st 2022
In this randomized trial from Poland, Norway, Sweden, and the Netherlands, the study population of approximately 85,000 individuals were randomly assigned to colonoscopy screening or usual care. The risk of colorectal cancer at 10 years was 18% lower in the screening cohort.
Family Medicine/General Practice October 26th 2022
ReachMD
Offering 0.25 credits, this 30-minute CME program discusses the new cervical cancer screening guidelines recently published by both the American Society for Colonoscopy and Cervical Pathology (ASCCP) and the American Cancer Society (ACS).
Obstetrics & Gynecology July 13th 2022
MedPage Today
Technology to the rescue. Employing artificial intelligence (AI) during a colonoscopy could save money and lead to earlier detection of cancer and better health outcomes for patients. AI detection tools also were associated with a cost savings of $57 per patient after lowering discounted costs from $3,400 to $3,343, which persisted in secondary colonoscopy modeling analysis.
Family Medicine/General Practice June 7th 2022
Conexiant
This is a 1.75-hour credit expert round-table featuring members of UPMC faculty. The group dialogue together on the state-of the art in pancreatic cancer and their experience in biliary stenting including advantages of metal versus plastic stenting, and their experience in recent advances in molecular testing of pancreatic cysts, identifying those patients that will benefit from targeted surveillance of pancreatic cancer, and methods of performing PDAC surveillance and their outcomes. They also discuss prevention and management of post-op complications, and pain control in this population.
Oncology, Medical May 31st 2022